KR960703908A - 정신병 치료방법(Antipsychotic method) - Google Patents

정신병 치료방법(Antipsychotic method) Download PDF

Info

Publication number
KR960703908A
KR960703908A KR1019960700807A KR19960700807A KR960703908A KR 960703908 A KR960703908 A KR 960703908A KR 1019960700807 A KR1019960700807 A KR 1019960700807A KR 19960700807 A KR19960700807 A KR 19960700807A KR 960703908 A KR960703908 A KR 960703908A
Authority
KR
South Korea
Prior art keywords
azabicyclo
thiadiazol
octane
exo
endo
Prior art date
Application number
KR1019960700807A
Other languages
English (en)
Inventor
포터 바이마스터 프란클린
이. 샤논 할란
사우어베르그 페르
에이취. 올레센 프레벤
스텐리 워드 존
에이취. 미취 챨스
Original Assignee
안네 세커
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안네 세커, 노보 노르디스크 에이/에스 filed Critical 안네 세커
Publication of KR960703908A publication Critical patent/KR960703908A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Cosmetics (AREA)
  • Epoxy Resins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

본 발명의 방법은 하기 일반식(Ⅰ)의 화합물 유효량을 정신분열증 또는 정신 분열형 질환에 걸렸거나 걸리기 위한 환자에게 투여함을 포함한다.
상기 식에서, x는 산소 또는 황이고, g는 아자비사이클릭 환
(여기서, 티아디아졸 또는 옥사디아졸 환은 아자비 사이클릭 환의 어떠한 탄소원자에도 결합할 수 있다)중의 하나로부터 선택된다.

Description

정신병 치료방법(Antipsychotic method)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용되는 이의 염 유효량을 정신 분열증 또는 정신 분열형 질환에 걸린 환자에게 투여함을 포함하는, 정신 분열증 또는 정신 분열형 질환을 치료하는 방법.
    상기 식에서, X는 산소 또는 황이고, R은 수소, 아미노, 할로겐, -CHO, -NO2, PR4, -Y, -NHCO-R4, -OR4, -SR4, SOR4, -SO2R4, C3-10-사이클로알킬, 4c-10-사이클로알케본 C4-10-(사이클로알킬알킬), -Z1-C4-10-사이클로알킬, -Z1-C4-10-사이클로알케닐, -Z1-C4-10-(사이클로알킬알킬), -Z1-C4-10-(사이클로알케닐알킬), -Z1-C4-10-(메틸렌사이클로알킬알킬), -NH-R4, -NR4R5, -NH-OR4, -CH=NOR4, 페닐, 벤질옥시카보닐, 페녹시, 벤조일, 테트라하이드로나프틸, 나프틸 또는 인데닐(여기서, 각각의 방향족 그룹은 임의로 할로겐, -NO2, -CN, C1-4-알킬, C1-4-알콕시, -OCF3, -CONH2, -CSNH2, 페녹시 또는 페닐에 의해 치환된다)이거나, R은 Z-R6-Z2-R5, Z1-R|6-Z2-R7-Z3-R5, -Z1-CO-R5, -Z1-R6-CO-R5, -Z1-R6-CO2-R5, -Z1-R6-CONH-R5, -Z1-R6-NHCO-R|5, -Z1-R6-Y 또는 -Z1-R6-Z2-Y[여기서, Z1및 Z2는 독립적으로 산소 또는 황이고, R4및 R5는 독립적으로 직쇄 또는 측쇄 , C1-15-알킬, 직쇄 또는 측쇄 C2-15-알케닐, 직쇄 또는 측쇄 C2-15-알키닐 {이들은 각각 임의로 하나 이상의 할로겐(들), C1-4-알콕시, -CF3, -CN, -COOH, -ON, -NH2, C1-4-알킬 에스테르, -SH, -NHR4, NR4R5, 페닐 또는 페녹시(여기서, 각각의 방향족 그룹은 임의로 할로겐, -NO2, -CN, C1-4-알킬, C1-4-알콕시, -OCF3, -CONH2, -CSNH2, 페닐 또는 페녹시에 의해 치환된다)에 의해 치환된다}이며, R6및 R7은 독립적으로 직쇄 또는 측쇄 C1-10-알킬렌, 직쇄 또는 측쇄 C2-10-알케닐렌, 직쇄 또는 측쇄 C2-10-알키닐렌{이들은 각각 임의로 하나 이상의 할로겐(들), -CF3, -CN, -COOH, -OH, -NH2, C1-6-알킬 에스테르, -SH, -NHR4, NR4R5, 페닐 또는 페녹시에 의해 치환된다}이고, Y는 1개 내지 4개위 N, O 또는 S 원자(들) 또는 이의 조합을 함유하는 5 또는 6원 헤테로사이클릭 그룹{여기서, 당해 그룹은 임의로 탄소 또는 질소원자(들)가 직쇄 또는 측쇄 C1-6-알킬, 페닐 또는 벤질에 의해 치환되거나, 산소원자와 함께 헤테로사이클릭 그룹 중의 탄소원자가 카보닐 그룹을 형성하거나, 또는 헤테로사이클릭 그룹이 임의로 페닐 그룹과 함께 융합된다}이다]이며, G는 아자비사이클릭 환
    중의 하나[여기서, 티아디아졸 또는 옥사디아졸 환은 아자비사이클릭 환의 어떠한 탄소원자에도 결합될 수 있고; R1및 R2는 티아디아졸 또는 옥사디아졸 환의 결합 위치를 포함하여 어떠한 위치에서도 존재할 수 있으며, 독립적으로 수소, 직쇄 또는 측쇄 C1-5-알킬, 직쇄 또는 측쇄 C2-5-알케닐, 직쇄 또는 측쇄 C2-5-알키닐, 직쇄 또는 측쇄 C1-10-알콕시, -OH에 의해 치환된 직쇄 또는 측쇄 C1-5-알킬, -OH, 할로겐, -NH2또는 카복시이며; R3은 H, 직쇄 또는 측쇄 C1-5-알킬, 직쇄 또는 측쇄 C2-5-알케닐 또는 직쇄 또는 측쇄 C2-5-알키닐이고; n은 0,1 또는 2이며; m은 0,1 또는 2이고; p는 0,1 또는 2이며; q는 1 또는 2이고;은 단일결합 또는 이중결합이다]로부터 선택된다.
  2. 제 1항에 있어서, X는 S이고, G가
    (여기서, n은 1이고, p는 1 또는 2이며, m은 1 또는 2이고, R1및 R2는 독립적으로 수소, 메틸, 메톡시, 하이드록시, 할로겐 또는 아미노이다)인 방법.
  3. 제 1항에 있어서, X는 S이고, G가
    (여기서, n은 1이고, p는 1 또는 2이며, m은 2이고, R1및 R2는 수소이다)인 방법.
  4. 제 1항에 있어서, X는 S이고, G가
    (여기서, n은 2이고, p는 1이며, m은 1이고, R1및 R2는 수소이다)이며, R4가 직쇄 또는 측쇄 C1-15-알킬인 방법.
  5. 제 1항에 있어서, X는 S이고, G가
    (여기서, n은 2이고, p는 1이며, m은 1이고, R1및 R2는 수소이다)이며, R4가 직쇄 또는 측쇄 C4-15-알킬인 방법.
  6. 제 1항에 있어서, X는 S이고, G가
    (여기서, n은 2이고, p는 1이며, m은 1이고, R1및 R2는 수소이다)이며, R4가 직쇄 또는 측쇄 C3-5-알킬인 방법.
  7. 제 1항에 있어서, 화합물이 3-클로로-3-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-클로로-3-(3-클로로-1,2,5-티아디아졸-4-일)-3-하이드록시-1-아자비사이클로[2,2,2]옥탄; 3-메톡시-3-(3-메톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3- (3-메톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥트-2-엔; 3-(3-헤실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥트-2-엔; 3-(3-헤실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2.2.2]옥탄; 3- (3-헥실옥시-1,2,5-티아디아졸-4-일)-3-하이드록시-1-아자비사이클로[2.2.2]옥탄; 3- (3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2.2.2]옥탄; 3- (3-에톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-프로폭시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-부톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(4-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 엑소-6-(3-클로로)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-클로로)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-헥실티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(5-헥세닐티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(3-페닐프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4-시아노벤질티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-에톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-에톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-3-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-메톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-3-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]헵탄; 엑소-6-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]헵탄; 엑소-6-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]헵탄; 엔도-3-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-3-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-3-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-3-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-3-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-3-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 3-클로로-2-(3-에톡시-1,2,5-티아디아졸-4-일)-8-아자비사이클로[3,2,1]옥트-2-엔; 3-(3-헥실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(5-헥세닐옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(3-헥세닐옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-펜틸옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-이소펜틸옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-헥실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-헵틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 엔도-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-3-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 3-클로로-2-(3-클로로-1,2,5-티아디아졸-4-일)-8-아자비사이클로[3,2,1]옥트-2-엔; 엑소-6-(3-펜틸옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 4-클로로-3-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 4-클로로-3-(3-프로필옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 4-클로로-3-(3-펜틸옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 4-클로로-3-(3-메톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 4-클로로-3-(1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; (-) 3-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; (+) 3-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-아미노-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 5-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 5-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-부틸설포닐-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2,2,3,3,4,4,4,-헵타플루오로부틸옥시)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-메톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-에톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-프로폭시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-부톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-펜틸옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-헥실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-이소헥실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2-부티닐옥시)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(3-(2-티에닐)-1-프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(3-(2-티에닐)-1-프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4,4,4-트리플루오로부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(6,6,6-트리플루오로부틸티오-1-헥실티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-부틸설포닐)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-(4,4,4-트리플루오로부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 3-(1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 엑소-3-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-3-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-(2-페녹시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-(2-티에닐)프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엔도-3-(3-(2-페닐티오)에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-6-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-헵틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-이소헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-이소펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4-시아노부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-시아노메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2-시아노에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(3-시아노프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4-시아노벤질티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2-페녹시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-벤질티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(2-페녹시에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-이소펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-이소헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-벤질티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-시아노메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(2-시아노에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(3-시아노프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4-시아노부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 4-클로로-3-(3-부톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 4-클로로-3-(3-헥실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 3-(3-부톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 3-(3-메톡시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 3-(3-프로폭시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 3-(3-헥실옥시-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,3,1]논-3-엔; 3-(3-이소펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(1-메틸프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-이소부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(2-페녹시에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-시아노메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(3-(2-티에닐)프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(4-클로로부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(1-메틸테트라졸-5-일티오)부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(2-메틸-1,3,4-티아디아졸-5-일티오)부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(4-(2-벤조티아졸릴)티오)부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(4-에틸벤질옥시)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(3-(2-티에닐)프로폭시)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; (+)-엑소-6-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 3-(3-(N-(2-에틸티오)프탈이미드)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(2-메톡시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(2-(1,3-디옥살란-2-일에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-사이클로프로필메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(4-플루오로벤질티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 엑소-6-(3-(4-클로로벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4-메틸벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4-트리플루오로메톡시벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4-티오카바밀벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4-메틸설포닐벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(5,5,5-트리플루오로펜틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(3,3,3-트리플루오로프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4-트리플루오로메톡시벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4-메틸벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4-플루오로벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-(5R,6R)-6-(3-프로필설포닐-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-(5S,6S)-6-(3-프로필설포닐-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-(5R,6R)-6-(3-(4-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-(5S,6S)-6-(3-(4-시아노벤질티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-(5R,6R)-6-(3-이소헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-이소헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-이소헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-(5R,6R)-6-(3-(4,4,4-트리플루오로부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-(5R,6R)-6-(3-(4,4,4-트리플루오로부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-(5R,6R)-6-(3-(4-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-(5R,6R)-6-(3-(4-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(3,3,3,-트리플루오로프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(3-(2-티에닐)프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(4,4,4,-트리플루오로부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-(3,3,3,-트리플루오로프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-3-(3-(4-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-6-(3-사이클로프로필메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2-(1,3-디옥살란-2-일)-에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4-메톡시벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2-메톡시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(3-하이드록시프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(4,4,4-트리플루오로부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-사이클로프로필메틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4-메톡시벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(2-메톡시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(4-트리플루오로메틸벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 5-(3-(4-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-프로필설포닐)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 2-메틸-6-클로로-6-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 8-메틸-6-클로로-6-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-2-메틸-6-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-2-메틸-6-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-8-메틸-6-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-6-(3-메틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-6-(3-에틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-6-(3-펜틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-6-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(4-트리플루오로메틸벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(4-니트로벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(2-하이드록시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-2-메틸-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-8-메틸-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-2-메틸-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-8-메틸-6-(3-프로필티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-2-메틸-6-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-8-메틸-6-(3-부틸티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-2-메틸-6-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-8-메틸-6-(3-헥실티오-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 6-클로로-6-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 3-클로로-3-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,1]헵탄; 엑소-6-클로로-6-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-클로로-6-(3-클로로-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엑소-6-(3-(2-트리플루오로메틸벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 엔도-6-(3-(2-시아노벤질티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; 3-(3-(2-하이드록시부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(2-부타노닐티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄 옥살레이트; 3-(3-(3-페녹시벤질옥시)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(4-카복시부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(3-하이드록시부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; 3-(3-(4-하이드록시부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; (+) 3-(3-부틸설포닐-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; (+) 3-(3-(2-부타노닐티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; (+) 3-(3-(2-하이드록시부틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[2,2,2]옥탄; (+)-엑소-6-(3-(2-프로파노닐티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(2-하이드록시프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-6-(3-(3-페닐프로필티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엑소-6-(3-(4-플루오로페녹시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엑소-6-(3-(4-플루오로페녹시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (+)-엔도-6-(3-(4-플루오로페녹시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄; (-)-엔도-6-(3-(4-플루오로페녹시에틸티오)-1,2,5-티아디아졸-4-일)-1-아자비사이클로[3,2,1]옥탄 및 약제학적으로 허용되는 이들의 염 중에서 선택되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700807A 1993-08-19 1994-08-18 정신병 치료방법(Antipsychotic method) KR960703908A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10928593A 1993-08-19 1993-08-19
US08/109,285 1993-08-19
PCT/DK1994/000309 WO1995005379A1 (en) 1993-08-19 1994-08-18 Antipsychotic method

Publications (1)

Publication Number Publication Date
KR960703908A true KR960703908A (ko) 1996-08-31

Family

ID=22326851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700807A KR960703908A (ko) 1993-08-19 1994-08-18 정신병 치료방법(Antipsychotic method)

Country Status (23)

Country Link
US (3) US5968926A (ko)
EP (1) EP0714394B1 (ko)
JP (1) JP3474575B2 (ko)
KR (1) KR960703908A (ko)
CN (1) CN1040979C (ko)
AT (1) ATE202353T1 (ko)
CA (1) CA2169838C (ko)
CZ (1) CZ42796A3 (ko)
DE (1) DE69427537T2 (ko)
DK (1) DK0714394T3 (ko)
ES (1) ES2160127T3 (ko)
FI (1) FI960748A (ko)
GR (1) GR3036587T3 (ko)
HU (1) HU222116B1 (ko)
IL (1) IL110727A (ko)
NO (1) NO310597B1 (ko)
NZ (2) NZ271313A (ko)
PT (1) PT714394E (ko)
SG (1) SG55072A1 (ko)
TW (1) TW442285B (ko)
UA (1) UA43347C2 (ko)
WO (1) WO1995005379A1 (ko)
ZA (1) ZA946321B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT714394E (pt) * 1993-08-19 2001-12-28 Novo Nordisk As Metodo antipsicotico com derivados de tiadiazol e oxadiazol
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5929247A (en) * 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
PE17897A1 (es) * 1995-02-17 1997-06-12 Lilly Co Eli Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
AU1128297A (en) * 1995-12-06 1997-06-27 Eli Lilly And Company Composition for treating pain
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
AU7107998A (en) * 1997-04-11 1998-11-11 Eli Lilly And Company Method for treating schizophrenia
JP2002503224A (ja) * 1997-04-11 2002-01-29 エリ リリー アンド カンパニー 疼痛を処置するための組成物
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
UA99936C2 (en) * 2007-11-21 2012-10-25 Эбботт Леборетриз Biaryl substituted azabicyclic alkane derivatives
WO2009140483A1 (en) 2008-05-15 2009-11-19 University Of Toledo Muscarinic agonists as cognitive enhancers
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789039T2 (de) * 1986-06-27 1994-06-09 Beecham Group Plc Verbrückte bicyclische N-heterocyclische Verbindungen.
US4977176A (en) * 1987-01-31 1990-12-11 Sandoz Ltd. Pilocarpine compounds which are used as pharmaceutical agents
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
PT714394E (pt) * 1993-08-19 2001-12-28 Novo Nordisk As Metodo antipsicotico com derivados de tiadiazol e oxadiazol

Also Published As

Publication number Publication date
JPH09501659A (ja) 1997-02-18
DK0714394T3 (da) 2001-10-01
IL110727A (en) 1998-08-16
PT714394E (pt) 2001-12-28
HUT73854A (en) 1996-09-30
US5968926A (en) 1999-10-19
EP0714394B1 (en) 2001-06-20
WO1995005379A1 (en) 1995-02-23
HU9600363D0 (en) 1996-04-29
NO960620D0 (no) 1996-02-16
AU7490494A (en) 1995-03-14
DE69427537T2 (de) 2002-04-04
US5679686A (en) 1997-10-21
ES2160127T3 (es) 2001-11-01
NO310597B1 (no) 2001-07-30
CN1133044A (zh) 1996-10-09
HU222116B1 (hu) 2003-04-28
FI960748A0 (fi) 1996-02-19
JP3474575B2 (ja) 2003-12-08
DE69427537D1 (de) 2001-07-26
CA2169838A1 (en) 1995-02-23
ZA946321B (en) 1996-02-19
SG55072A1 (en) 1998-12-21
UA43347C2 (uk) 2001-12-17
NZ336596A (en) 2001-02-23
CN1040979C (zh) 1998-12-02
AU697529B2 (en) 1998-10-08
CA2169838C (en) 2002-06-11
IL110727A0 (en) 1994-11-11
NZ271313A (en) 1999-09-29
TW442285B (en) 2001-06-23
FI960748A (fi) 1996-04-18
CZ42796A3 (en) 1996-12-11
ATE202353T1 (de) 2001-07-15
GR3036587T3 (en) 2001-12-31
EP0714394A1 (en) 1996-06-05
NO960620L (no) 1996-04-18
US5677313A (en) 1997-10-14

Similar Documents

Publication Publication Date Title
KR960703908A (ko) 정신병 치료방법(Antipsychotic method)
RU95118133A (ru) Гетероциклические соединения, способы их получения и фармацевтическая композиция
RU2009120229A (ru) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
AU2012210652B2 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
DE3880396T2 (de) Zur Behandlung von neurodegenerativen Erkrankungen verwendbare Kynurensäurederivate.
FI911885A (fi) Menetelmä terapeuttisesti käyttökelpoisten 2,9-disubstituoitujen 3-/2-/4-(6-fluori-1,2-bentsisoksatsol-3-yyli)-piperidinyyli/etyyli/-4H-pyrido/1,2-a/pyrimidin-4-onien valmistamiseksi
IE904603A1 (en) Pharmaceuticals
WO2011009890A2 (en) Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
KR900002777A (ko) 정신분열증 및 정신병 치료 또는 예방제
DE69516076D1 (de) Tetrahydropyridin Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
JP2005504059A5 (ko)
RU96105389A (ru) Антипсихотический способ
DD207200A1 (de) Verfahren zur herstellung substituierter dibenzodiazepinone
US5726193A (en) Method for treating anxiety
US5484794A (en) Method for treating anxiety
WO1997025043A1 (en) A method of treating hypercholesterolemia and related disorders
IL125371A (en) 2,3,8,-TRISUBSTITUTED IMIDAZO [1,2-a] PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee